 |
allogeneic Epstein-Barr virus cytotoxic T lymphocytes |
|---|---|
| Trade Name | |
| Orphan Indication | Epstein-Barr virus-positive post-transplant lymphoproliferative disorders |
| USA Market Approval | USA |
| USA Designation Date | 2016-02-04 00:00:00 |
| Sponsor | ATARA Biotherapeutics, Inc.;4360 Park Terrace Drive, Suite 100;Westlake Village, California, 91361 |
